Intersect ENT, Inc. (NASDAQ:XENT) has been given an average recommendation of “Hold” by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.00.
Several equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating and set a $21.00 price target on the stock in a report on Tuesday, April 20th. SVB Leerink lifted their price target on shares of Intersect ENT from $24.00 to $25.00 and gave the company a “market perform” rating in a report on Tuesday, March 16th. Piper Sandler lifted their price target on shares of Intersect ENT from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Friday, January 15th. Finally, Canaccord Genuity raised shares of Intersect ENT from a “hold” rating to a “buy” rating and lifted their price target for the company from $18.00 to $25.00 in a report on Monday, January 11th.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Great Lakes Advisors LLC increased its position in Intersect ENT by 5.6% in the first quarter. Great Lakes Advisors LLC now owns 263,947 shares of the medical equipment provider’s stock worth $5,511,000 after purchasing an additional 13,928 shares during the last quarter. Susquehanna International Group LLP bought a new stake in Intersect ENT in the fourth quarter worth $242,000. Morgan Stanley increased its position in Intersect ENT by 1,138.6% in the fourth quarter. Morgan Stanley now owns 173,085 shares of the medical equipment provider’s stock worth $3,965,000 after purchasing an additional 159,111 shares during the last quarter. Nuveen Asset Management LLC increased its position in Intersect ENT by 17.8% in the fourth quarter. Nuveen Asset Management LLC now owns 710,029 shares of the medical equipment provider’s stock worth $16,260,000 after purchasing an additional 107,455 shares during the last quarter. Finally, Gyon Technologies Capital Management LP bought a new stake in Intersect ENT in the fourth quarter worth $747,000. Institutional investors own 84.32% of the company’s stock.
NASDAQ XENT traded down $0.65 during trading hours on Thursday, hitting $21.89. 96,269 shares of the company’s stock traded hands, compared to its average volume of 205,921. The business’s fifty day moving average price is $20.57 and its two-hundred day moving average price is $21.31. The company has a current ratio of 11.28, a quick ratio of 10.29 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $725.35 million, a P/E ratio of -11.40 and a beta of 1.34. Intersect ENT has a 52 week low of $10.84 and a 52 week high of $26.98.
Intersect ENT (NASDAQ:XENT) last announced its earnings results on Monday, March 8th. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.22). The business had revenue of $28.20 million for the quarter, compared to the consensus estimate of $27.83 million. Intersect ENT had a negative net margin of 71.96% and a negative return on equity of 55.81%. The business’s quarterly revenue was down 11.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.25) earnings per share. On average, sell-side analysts expect that Intersect ENT will post -1.88 EPS for the current fiscal year.
About Intersect ENT
Intersect ENT, Inc operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Recommended Story: Overbought
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.